AB1055 CERTOLIZUMAB PEGOL: A SAFE AND EFFICIENT TREATMENT IN PATIENTS WITH UVEITIS DURING PREGNANCY.
نویسندگان
چکیده
منابع مشابه
Observed Incidence of Uveitis Following Certolizumab Pegol Treatment in Patients With Axial Spondyloarthritis
OBJECTIVE Axial spondyloarthritis (axial SpA) is characterized by inflammation of the spine and sacroiliac joints and can also affect extraarticular sites, with the most common manifestation being uveitis. Here we report the incidence of uveitis flares in axial SpA patients from the RAPID-axSpA trial, including ankylosing spondylitis (AS) and nonradiographic (nr) axial SpA. METHODS The RAPID-...
متن کاملPregnancy Outcomes in Subjects Exposed to Certolizumab Pegol.
OBJECTIVE To provide information on pregnancy outcomes in women receiving certolizumab pegol (CZP). METHODS The UCB Pharma safety database was searched for pregnancies through to September 1, 2014. Reports for maternal and paternal CZP exposure were included and outcomes examined, and data on CZP exposure, pregnancy, comorbidities, and infant events were extracted by 2 independent reviewers. ...
متن کاملCertolizumab pegol in the treatment of Crohn's disease.
INTRODUCTION The introduction of antibodies directed against tumour necrosis factor (anti-TNF) has dramatically changed the concept of treating patients with Crohn's disease (CD). Unfortunately, the long-term efficacy of anti-TNF agents may be hampered by immunogenicity. The availability of more anti-TNF agents in the therapeutic armamentarium would therefore be of great benefit in patients loo...
متن کاملSafe Pregnancy Ending by Laminaria and Uterine Discharge in Patients with Cesarean Section During the Second Trimester of Pregnancy
موضوع: هدف از این مطالعه بررسی رتروسپکتیو احتمال افزایش خطر در ختم حاملگی با لامیناریا و تخلیه رحمی در سه ماهه دوم در بیماران با سابقه اسکار رحمی می باشد. روش مطالعه: از سال ۱۹۷۸ تا ۱۹۹۳، ۱۰۶۴ بیمار با سن حاملگی ۲۲-۱۴ هفته که ۷۰ نفر آنها سابقه اسکار رحمی داشته و حاملگی آنان بوسیله لامیناریا و تخلیه رحمی خاتمه یافت مورد بررسی قرار گرفتند. نتایج: هیچ عارضه مهم جراحی نظیر عوارض بیهوشی و سوراخ شد...
متن کاملis certolizumab pegol safe and effective in the treatment of patients with moderate to severe crohn’s disease? a meta-analysis of controlled clinical trials
conclusions cp is effective for inducing clinical response and maintenance of clinical remission in patients with moderate to severe cd with similar side-effect profile as the control arms. background tumor necrosis factor-α (tnf-α) antibodies are currently used in patients with moderate to severe crohn’s disease (cd) who are unresponsive to conventional therapies. certolizumab pegol (cp) is on...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of the Rheumatic Diseases
سال: 2020
ISSN: 0003-4967,1468-2060
DOI: 10.1136/annrheumdis-2020-eular.1610